Skip to main content

Advertisement

Table 2 Antibody-drug conjugates in clinical trials for lymphoid malignancies

From: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

ADC names Target Linker Payload Indications Major responses Status [reference]
Brentuximab vedotin (Adcetrix®) CD30 Protease-cleavable (Val-Cit) MMAE R/R HL ORR 75%, CR 34%; OS 40.5 months, PFS 9.3 months; 5-year OS 41%, PFS 22%; Approved [54]
Frontline stage III & IV HL (+ AVD) ORR 86%, CR 73%, 2-year PFS 81% Approved [51]
Post-ASCT consolidation for HL PFS 42.9 months, 5-year PFS 59% Approved [60, 61]
R/R systemic ALCL ORR 86%, CR 57%, 5-year OS 79%, PFS 57%, DOR 25.6 months Approved [65, 66]
R/R PTCL (+ CHP) ORR 83%, CR 68%, PFS 48.2 months Approved [67]
R/R CTCL ORR 56.3%, CR 16%, PFS 17.2 months Approved [68]
Inotuzumab ozogamicin (Besponsa®) CD22 Acid-labile (hydrazone) Calicheamicin R/R B-cell ALL, CR/CRi 73.8%, OS 7.7 mo, PFS 5 months Approved [74, 75]
Frontline Ph- B-cell ALL (+ miniHCVD) ORR 98%, CR 85%, 3-year OS 56%, PFS 49% Phase II [82]
R/R B-cell NHL ORR 67%, CR 31%, PFS 12.7 months Phase II [89]
Moxetumomab pasudotox (Lumoxiti®) CD22 Disulfide bond PE38 R/R HCL ORR 75%, CR 41%, PFS not reached at 16.7-month follow up Approved [97, 98]
Polatuzumab vedotin (DCDTS4501A) CD79b Protease-cleavable (Val-Cit) MMAE R/R DLBCL (+ BR) ORR 63%, PFS 7.6 months, OS 12.4 months Approved [103]
Newly diagnosed DLBCL (+ G-CHP or + R-CHP) G-CHP: ORR 91%, CR 81%; R-CHP: ORR 91%, CR 78%; Phase III [105, 106]
Coltuximab ravtansine (SAR3419) CD19 Disulfide bond (SPDB) DM4 R/R DLBCL ORR 43.9%, CR 14.6%, OS 9.2 months, PFS 4.4 months Phase II [109]
Denintuzumab mafodotin (SGN-CD19A) CD19 Non-cleavable (MC) MMAF R/R B-cell ALL ORR 35%, CR 19%, DOR 27 weeks Phase I [110]
R/R DLBCL ORR 33%, CR 22%, DOR 40 weeks Phase I [111]
Loncastuximab Tesirine (ADCT-402) CD19 Protease-cleavable (Val-Ala) PBD dimer R/R B-cell ALL CR 8.7% Phase I [112]
R/R NHL DLBCL: ORR 40.2%, CR 22% MCL: ORR 46.7%, CR 26.7%; FL: ORR 80%, CR 53.3% Phase I [113, 114]
Pinatuzumb vedotin (DCDT2980S) CD22 Protease-cleavable (Val-Cit) MMAE R/R B-cell NHL (+ Rituximab) DLBCL: ORR 60%, CR 26%, PFS 5.4 months; FL: ORR 62%, CR 5%, PFS 12.7 months Phase II [103]
Camidanlumab tesirine (ADCT-301) CD25 Protease-cleavable (Val-Ala) PBD dimer R/R HL ORR 80.8%, CR 50%, DOR 7.7 months, PFS 6.7 months Phase I [115]
R/R B and T cell NHL B: ORR 31.3%, CR 18.8%; T: ORR 50%, CR 0 Phase I [116]
Naratuximab emtansine (IMGN529) CD37 Non-cleavable (SMCC) DM1 R/R B-cell NHL ORR 13%, CR 2.6% Phase I [117]
AGS67E CD37 Protease-cleavable (Val-Cit) MMAE R/R B and T cell NHL ORR 22%, CR 14% Phase I [118]
  1. ADC antibody-drug conjugate, ALCL anaplastic large cell lymphoma, ALL acute lymphoblastic leukemia, CTCL cutaneous T cell lymphoma, HL Hodgkin lymphoma, NHL non-Hodgkin lymphoma, R/R relapsed/refractory, MM multiple myeloma, CR complete remission, DLBCL diffuse large cell lymphoma, DOR duration of response, FL follicular lymphoma, MCL mantle cell lymphoma, ORR overall response rate, OS overall survival, PFS progression-free survival, PTCL peripheral T cell lymphoma